{"url":"https://newsforagent.com/news/2026-10-22/pleopharma-cannabis-withdrawal-survey","markdown_url":"https://newsforagent.com/news/2026-10-22/pleopharma-cannabis-withdrawal-survey.md","title":"PleoPharma to Present Cannabis Withdrawal Survey Data","headline":"PleoPharma to Present Survey of 146 Women on Cannabis Withdrawal at Menopause Society Meeting","description":"PleoPharma will present survey data showing 90% of 146 women reported at least one cannabis withdrawal symptom.","section":"Research & Clinical Trials","published_at":"2026-10-22T15:57:43+00:00","modified_at":"2026-10-22T15:57:43+00:00","author":"News Desk","key_takeaways":["PleoPharma will present survey findings on October 22 at The Menopause Society's 2026 Annual Meeting in San Diego.","The survey of 146 women found 90% reported at least one withdrawal symptom and 61% said symptoms began within 24 hours of last use.","PleoPharma is developing PP-01, a once-daily oral product intended to mitigate cannabis withdrawal in patients with cannabis use disorder."],"companies":[{"name":"PleoPharma","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000m83/pleopharma","website":"https://pleopharma.com"},{"name":"Bryter","is_primary":false,"profile_url":"https://akta.pro/company-profiles/000nxnv/bryter","website":"https://www.bryter-uk.com"}],"source":{"publisher":"PR Newswire","title":"PLEOPHARMA TO PRESENT SURVEY DATA ON CANNABIS WITHDRAWAL IN WOMEN SEEKING CANNABIS CESSATION PleoPharma, Inc. October 22","url":"https://www.prnewswire.com/news-releases/pleopharma-to-present-survey-data-on-cannabis-withdrawal-in-women-seeking-cannabis-cessation-pleopharma-inc-october-22-302917149.html"},"other_sources":[],"tags":["Research & Clinical Trials","PleoPharma","Bryter"],"body_markdown":"[PleoPharma](https://akta.pro/company-profiles/0000m83/pleopharma) will present survey data on women's cannabis withdrawal at The Menopause Society's 2026 Annual Meeting, the company said. The poster presentation covers 146 women who had tried to stop, reduce or take a break from cannabis, and it is scheduled for October 22 at 6:15-7:15 PDT in San Diego, according to [PR Newswire](https://www.prnewswire.com/news-releases/pleopharma-to-present-survey-data-on-cannabis-withdrawal-in-women-seeking-cannabis-cessation-pleopharma-inc-october-22-302917149.html).\n\n## What the PleoPharma Survey Found\n\nThe online research survey was performed by [Bryter](https://akta.pro/company-profiles/000nxnv/bryter). Of the 146 respondents, 90% reported at least one withdrawal symptom, 61% said symptoms began quickly within 24 hours of last use, and 12% within 3 hours. Overall, 84% of women reported seeking medical help to cut back or stop cannabis, or to manage withdrawal symptoms, and about two-thirds said they were interested in a medication assisted treatment for cannabis withdrawal or cannabis use disorder.\n\nPleoPharma is a clinical-stage development company in addiction medicine focused on cannabis-related health issues, based in Phoenixville, Pennsylvania. It is developing PP-01, an investigational once-daily oral product with rapid onset intended to mitigate cannabis withdrawal in patients with cannabis use disorder.\n\nShelli Graham, PhD., senior vice president of clinical research and medical affairs at PleoPharma, said, \"This research survey adds to the expanding body of evidence regarding women's experiences with cannabis dependence and highlights the need for a product to help those women trying to reduce their cannabis use.\"\n\n## PleoPharma's Funding and Trial Progress\n\nAccording to akta.pro [company records](https://akta.pro/company-data), PleoPharma has raised over $60 million since its founding in 2019, including a $36 million Series B round in October 2025 and a $17.5 million Series A round in June 2023. The same records list five funding rounds on file, among them a $6.5 million grant in August 2026 led by the National Institute on Drug Abuse and a $5.5 million debt-funded round that month.\n\nThe records also show PleoPharma dosed the first patient in June 2026 in the pivotal Phase 3 CAN-004 trial of PP-01 for cannabis withdrawal symptoms, and that it secured US Patent No. 12,268,659 in April 2025 covering method-of-use claims for PP-01 in mitigating cannabis withdrawal symptoms and improving sleep, with protection extending through March 2041.\n\n## Earlier PleoPharma Milestones\n\nIn August 2026, PleoPharma was awarded a $6.5 million, three-year grant from the National Institute on Drug Abuse to support its pivotal Phase 3 clinical trial of PP-01 for treating cannabis withdrawal symptoms in adults with cannabis use disorder, PR Newswire reported. In June 2026, the company announced its participation at the BIO International Convention 2026, held June 22-25 at the San Diego Convention Center, with its presentation scheduled for June 23, PR Newswire reported.\n\nThe company's website is [PleoPharma.com](https://pleopharma.com).\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}